While retrospective registry data suggest that treating traditional cardiovascular risk factors and optimizing treatment of skin disease reduces cardiovascular risk in psoriasis, randomized placebo-controlled trials with psoriasis treatments assessing impact on cardiovascular outcomes are lacking.9 However, the impact of psoriasis biologic therapy on coronary inflammation has been assessed in a prospective observational study involving 134 psoriasis patients with moderate to severe skin disease treated with anti-TNF-α, anti-IL-12/23, or anti-IL-17A. This evidence concerns the gene IL17A and psoriasis.